RR2 Resource Utilization Pattern And Cost Of Tuberculosis Treatment In Penang, Malaysia  by Atif, M. et al.
 VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 7 1 9 – A 8 1 3  A725
Stroke in China (TIMS-China) study. Efficacy data were derived from a pooled analy-
sis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Costs and quality-adjusted life-
years (QALYs) were compared both in short term (2 years) and in long term (30 years). 
One-way and probabilistic sensitivity analyses were performed to test the robust-
ness of the results. Results: Comparing to no tPA treatment, tPA treatment within 
4.5 hours has a gain of 0.101 QALYs at an additional cost of CNY 9,520 (US$ 1,460), 
yielding an incremental cost-effectiveness ratio (ICER) of CNY 94,300 (US$ 14,500) 
per QALY gained after 2 years, and a lifetime gain of 0.422 QALYs at an additional 
cost of CNY 6,530 (US$ 1,000), yielding an ICER of CNY 15,500 (US$ 2,380) per QALY 
gained. Probabilistic sensitivity analysis shows that tPA treatment is cost-effective 
in 98.7% of the simulations at a willingness-to-pay threshold of CNY 105,000 (US$ 
16,200) per QALY. ConClusions: Intravenous tPA treatment within 4.5 hours is 
highly cost-effective for acute ischemic stroke in China setting.
QA4
Cost-Utility of BevACizUmAB with PC Regimen in non-smAll Cell lUng 
CAnCeR tReAtment
Nguyen T.T.T., Tran T.T.H. 
University of Medicine and Pharmacy in HCMC, Ho Chi Minh City, Vietnam
objeCtives: Lung cancer, especially non-small cell lung cancer (NSCLC), is one 
of the most leading causes of mortality not only in the world but also in Vietnam. 
Bevacizumab – a targeted therapy agent- has been recommended to use in combina-
tion with chemotherapy as the first-line treatment of advanced NSCLC. However, the 
high cost of bevacizumab may reduce the availability of bevacizumab, especially in 
Vietnam. Therefore, this analysis was conducted to analyze the cost-effectiveness 
of bevacizumab in the combination with paclitaxel and carboplatin (BCP) versus 
paclitaxel and carboplatin regimen (PC) in Vietnamese setting. Methods: A Markov 
model has been developed with 3 stages (stable, progressive and death). The model 
has a cycle length of 1 year with the life-time horizon. The population of 1000 
patients was included in the  model. The transition rates have been retrieved from 
randomized clinical trials, the prices of drugs and medical services have been aver-
aged from the price-lists of some major hospitals in Vietnam in 2013. The sensitiv-
ity analysis has been conducted. Results: The cost of BCP and PC regimen for 
NSCLC treatment accounts for 4,691,452,387 VND and 1,792,656,298 VND with the 
QALY of 7.88 and 5.62, respectively. The CER of BCP regimen for NCSLC treatment 
accounts for 595,533,261 VND, which is around 2 times higher than that of PC regi-
men. The ICER of BCP regimen versus PC regimen accounts for around 1.3 billion 
VND, which is about 17 times higher than the willingness-to-pay of Vietnam (74 
million VND). One-way sensitive analysis showed bevacizumab price as the most 
affecting factor on its cost-effectiveness. ConClusions: Due to the high cost of 
drug, the combination of bevacizumab in the PC regimen in treatment of NSCLC 
is considered not cost-effective in Vietnam. To enhance the cost-effectiveness of 
bevacizumab, supporting policies from manufacturer, health care providers and 
government should be established.
ResPiRAtoRy – Related Disorders outcomes Research studies
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objeCtives:  To evaluate physician’s knowledge and adherence to asthma guideline 
adherence (GINA 2011) at emergency department of Hospital Pulau Pinang, Malaysia 
and to calculate cost of adhered and non-adhered prescriptions. Methods: 
A cross-sectional survey was conducted to evaluate knowledge of GINA, 2011 asthma 
guideline at emergency department of Hospital Pulau Pinang, Malaysia. A total of 
810 patient prescriptions of 27 doctors (30 prescriptions per doctor) were viewed 
to asses doctor’s guideline adherence. Patients’ prescriptions were categorised in 
terms of asthma severity as mild, moderate and severe. Prescriptions were labelled 
as adhered or non-adhered in terms of doctor treatment according to patient 
asthma severity as recommended by CPG (GINA 2011). Cost of adhered and non-
adhered was calculated according to asthma severity. Results: Twenty two (81.5%) 
doctor’s had adequate GINA, 2011 asthma guideline knowledge (Mean 16.7, SD ± 
1.5). Six hundred and twenty eight (77.5%) patients received guideline (GINA 2011) 
adhered pharmacotherapy. Six hundred and seventy eight (83.7%) patients asthma 
were classified as mild asthma, 128 (15.8%) patients were classified as moderate 
asthma and 4 (0.5%) patients were classified as severe asthma. Pearson correlation 
indicated no statistical significant association between asthma guideline adher-
ence and asthma guideline knowledge score (p= 0.27). Univariate analysis indicate 
that patients with age group 25-35 years and with hypertension as co-morbidity 
received significantly better pharmacotherapy (p= 0.04, p= 0.03 respectively). Total 
cost of 628 adhered prescriptions was RM 5792.87 whereas cost of 182 non-adhered 
prescriptions was RM 1759.09. Cost of single mild asthma adhered prescription 
(RM 9.18) was less as compared to non adhered mild asthma prescription (RM 
10.39). ConClusions: Emergency doctor’s had adequate GINA, 2011 asthma guide-
line knowledge. Majority of patients received GINA, 2011 asthma guideline adhered 
pharmacotherapy. Cost effective medication can significantly reduce socioeconomic 
burden related to asthma.
RR2
ResoURCe UtilizAtion PAtteRn AnD Cost of tUBeRCUlosis tReAtment 
in PenAng, mAlAysiA
Atif M.1, Sulaiman S.A.S.2, Shafie A.A.2, Asif M.2
1The Islamia University of Bahawalpur, Bahawalpur, Pakistan, 2Universiti Sains Malaysia, 
Penang, Malaysia
the usual clinic, medicines availability at the clinic in the community. Results: 
The average immunization propensity is 0.69 (7,668 of 11,114) with a mean value of 
0.57 for flu vaccine propensity. The upward trend over time in household income 
and percentage of residents in urban area indicate the rapid economic development 
and the urbanization in China from 2000 to 2006. Logit, probit, and longitudinal 
linear random effects regression analyses showed that maternal education level 
positively affects the immunization propensity for children aged ≤ 6 (p< 0.01) and for 
children aged 7-18 (p< 0.1). Other factor, such as the medical insurance, whether the 
individual resides in urban area and the needed medicines availability at the clinic, 
also had a significant impact on the immunization propensity for children and 
adolescents (p< 0.05). ConClusions: Maternal education positively affects chil-
dren’s immunization propensity, particularly for those children below 6 years of age.
QAly – Related studies
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objeCtives: The purpose of this study was to compare the performance of 
the EuroQol 5-dimension (EQ-5D-5L) and the Short Form 6-dimension (SF-6D) 
instruments in assessing Asian patients with end-stage renal disease (ESRD) in 
Singapore. Methods: In a cross-sectional study, we interviewed ESRD patients 
who were dialyzed or followed up at the National University Hospital using a battery 
of questionnaires including the EQ-5D-5L, the kidney disease quality of life instru-
ment (KDQOL-36), and questions assessing dialysis history and socio-demographic 
characteristics. We reviewed patients’ medical records for their clinical information. 
We assessed the construct validity of the EQ-5D-5L and SF-6D index scores and 
compared their ability to distinguish between patients in differing health status 
and the magnitude of between-group difference they quantified. Results: One 
hundred and fifty ESRD patients on dialysis (mean age: 60.1 years; female: 48.7%) 
participated in the study. Both EQ-5D-5L and SF-6D demonstrated good known-
groups construct validity; the EQ-5D-5L was more sensitive to differences in clinical 
outcomes and the SF-6D was more sensitive to differences in KDQOL scales. The 
intraclass correlation coefficient between the measures was 0.36. The differences 
in (both actual and derived) EQ-5D index score for patients in better and worse 
health status were greater than those in SF-6D index score. ConClusions: Both 
EQ-5D-5L and SF-6D are valid instruments for assessing ESRD patients. However, 
the two preference-based health index scores cannot be used interchangeably and 
it appears that EQ-5D-5L would lead to more favorable cost-effectiveness results 
than SF-6D if they are used in economic evaluations of interventions for ESRD.
QA2
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objeCtives: HTA in Taiwan was established in December 2007 to inform decision 
making on drug approvals and reimbursement prices. Drug categories were estab-
lished based on the therapeutic value and the innovative nature of new drugs, and 
various pricing structures were adopted. Price adjustments based on demonstra-
tive improvements in clinical efficacy and safety are also able to be applied. These 
adjustments can take into account clinical and pharmacoeconomic data specifically 
relevant to Taiwan. The aim of this study was to investigate the reimbursements of 
new health technologies assessed by the NIHTA with respect to drug categorisation, 
pricing structures and applied price adjustments. Methods: NIHTA assessment 
reports from 2011 to February 2014 were reviewed, and approval and pricing deci-
sions by the NHIA were evaluated. Results: Of the 52 assessments included in this 
analysis, 37 were approved for use on the National Health Insurance (NHI) in Taiwan. 
Of these, 57% were determined as having a comparable therapeutic value to the 
current best competitor, 38% were deemed to show moderate improvements and 
5% were considered breakthrough innovations. In most instances (73%), drugs were 
priced based on existing therapies. Of the approved health technologies, 9 (24%) were 
eligible for additional price adjustments. These were spread across multiple disease 
areas and reflected improved clinical and safety outcomes, dosing convenience and 
the availability of local clinical and economic data. The incidence of price adjust-
ments has increased in recent years, which is particularly evident with respect to high 
quality pharmacoeconomic data. ConClusions: The majority of drugs approved by 
the NHIA offer similar clinical benefit to current competitors and are priced based 
on existing therapies. Alternative methods involved calculating drug prices based 
on international reference countries, although manufacturers seem to be increas-
ingly seeking available price adjustments to achieve a higher price for their product.
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Cost-effeCtiveness of thRomBolysis within 4.5 hoURs of ACUte 
isChemiC stRoKe in ChinA
Pan Y.1, Wang Y.L.1, Liu G.1, Zhao K.2, Wang Y.1
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objeCtives: Previous economic studies conducted in developed countries showed 
intravenous tissue-type plasminogen activator (tPA) is cost-effective for acute 
ischemic stroke. This study aims to determine the cost-effectiveness of tPA treat-
ment in China setting. Methods: A combination of a decision tree and a Markov 
model was developed to determine the cost-effectiveness of tPA treatment versus 
no tPA treatment within 4.5 hours after stroke onset. Outcomes and costs data 
were derived from the Thrombolysis Implementation and Monitor of acute ischemic 
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objeCtives: Anti-cancer chemotherapeutic pharmaceutical agents have some 
toxic effects to normal cells. Therefore, the main factors to increase therapeutic 
effects are to destroy cancer cells specifically and appropriate dosage of anti-
cancerous agents. Cancer cells are have being studied in many ways by using cell 
culture technologies in developed countries. We aimed to determine the chemo-
sensitivity of colorectal cancer cases. Methods: From February 2013 through 
February 2014, Histoculture drug response assay data were obtained from 6 colo-
rectal cancer surgical specimens held in State Central Hospital. Cultures and 
culture media were prepared by R. Hoffmans methods. We examined chemosen-
sitivities of the tissue to carboplatin, irinotecan, doxorubicin, 5-fluorouracil and 
oxalaplatin. Cutoff inhibition rates were determined with each drug for colorectal 
cancer and were used to calculate predictabilities for chemosensitivity responses. 
We also prepared double samples from the culture and made histologic and cyto-
logic analysis. Results: The evaluability of the histoculture drug response assay 
was at 83,3%. Predictability including true-positive and true-negative rates of 83,3% 
and 100% was observed. ConClusions: Cancer cells deaths are dependent from 
dosages of the candidate medications and it shows it is possible to use drug sen-
sitivity methods in oncologic clinical practice.
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objeCtives: Various studies exploring the routine use of corticosteroids for man-
agement of acute respiratory distress syndrome have had controversial results. 
The aim of this study was to evaluate and compare randomized, controlled trials 
with observational studies (comparing historical controls) determining the effi-
cacy and safety of steroids in management of Acute Respiratory Distress Syndrome 
in adult population. Methods: English language, randomized control trial and 
observational studies were searched using different  databases like the Cochrane 
Central Register of Controlled Trials, Cochrane database of systematic reviews, 
PUBMED, SCOPUS, SCIENCE DIRECT (Key terms: corticosteroids, methylprednisolone, 
hydrocortisone, dexamethasone AND acute lung injury, adult respiratory distress syn-
drome, acute respiratory distress syndrome, ARDS, respiratory failure, septic shock; years: 
inception to February 2014). Results: A total of 8 randomized control trial and 5 
observational studies using variable dose and duration of steroids met the inclu-
sion criteria. The Mantel-Hanzel odds ratio of corticosteroids decreasing mortality 
in patients of randomized, controlled trial was 0.822; 95% CI 0.480 to 1.408 whereas 
in observational studies was 0.552; 95% CI 0.134 to 2.278. The odds of corticoster-
oids associated infectious complications in patients of randomized, controlled 
trial was 1.118; 95% CI 0.557 to 2.247 whereas in observational studies was 1.662; 
95% CI 0.981 to 2.816. ConClusions: A definitive role of corticosteroids in ARDS 
has not been established. However, current data from studies shows the result 
favouring use of corticosteroids in ARDS by decreasing the mortality associated. 
However, use of steroids is associated with a slight risk of increased infectious 
complications.
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objeCtives: Acute respiratory distress syndrome (ARDS) is an acute hypoxemic 
respiratory failure. It is the most severe form of acute lung injury. The treatment 
of ARDS is generally supportive and there is ambiguity in the role of glucocorti-
coids in the treatment of ARDS. This study aimed at analyzing treatment pattern 
and outcome of patients in ARDS. Methods: A retrospective observational study 
was conducted in a tertiary care teaching hospital. All the patients diagnosed 
with ARDS confirmed by chest X-ray and arterial blood gas during 2011 were 
included. Cases were identified and collected from the medical records division 
using ICD code J86. Results: A total of 150 patients diagnosed with ARDS were 
included in the study. Mean age of the study population was 43.37 ± 16.15 years. 
Majority of them were males, 60.7% of the population. Analyzing the treatment 
pattern, 98.6% were given antibiotics for their underlying conditions along with 
supportive therapies, 48.6% of patients received glucocorticoid therapy and was 
found to be beneficial. Outcome analysis revealed 50.7% of patients recovered 
and 45.3% expired. Higher mortality (56.4%) was observed in the group who did 
not receive glucocorticoid therapy compared to the group which received gluco-
corticoid therapy (41.7%). ConClusions: The overall mortality rate was found 
to be high in ARDS patients in this study and use of glucocorticoids showed ben-
eficial effects.
objeCtives: The aim of this study was to analyze the tuberculosis-related medical 
resource utilization pattern among new smear positive pulmonary tuberculosis 
(PTB) patients. We also estimated the cost of tuberculosis (TB) treatment from the 
perspective of provider and patient, and identified the significant cost driving fac-
tors. Methods: All new smear positive PTB patients who were registered at the 
chest clinic of Penang General Hospital, between March 2010 and February 2011, 
were invited to participate in the study. Provider sector costs were estimated using 
bottom-up, micro-costing technique. For the calculation of costs from the patients’ 
perspective, all eligible patients who agreed to participate in the study were inter-
viewed after the intensive phase and at end of their treatment by a trained nurse. 
Predictive Analysis SoftWare was used to analyze the data. Results: During the 
study period, 226 patients completed the treatment. However, complete costing 
data were available for 212 patients. The most highly utilized resource was chest 
X-rays followed by sputum smear examination and non-specific laboratory tests. 
Only a smaller proportion of the patients were hospitalized. The total cost of treat-
ing a smear positive PTB patient was USD 727.24. The amount paid by the patient 
constituted 55.3% (USD 401.90) of the total average cost of TB treatment. In multiple 
linear regression analysis, prolonged treatment duration (i.e., > 6 months) was the 
only predictor of higher provider sector cost, whereby higher patient sector cost 
were determined by greater household income and persistent cough at the end of 
the intensive phase of the treatment. ConClusions: The average provider sector 
cost was 1.45 times higher (USD 325.35 versus USD 225.00) than the budget allocated 
by the Ministry of Health for the treatment of a TB case in Malaysia. The expenses 
borne by the patients and their families accounted for 5.71% of their annual family 
income, hence not catastrophic.
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AwARness AnD PRevention of ChRoniC DiseAses in JAPAn
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objeCtives: Chronic diseases are common and costly to society, but often pre-
ventable. This study focuses on better understanding awareness and prevention of 
chronic diseases in Japan. Methods: This study included data for the 2012 Japan 
(N= 30,000) National Health and Wellness Survey, a cross-sectional, Internet-based 
survey of adults (18+ years) who provide information on their comorbidities, and 
health care behaviors. Awareness of chronic diseases were assessed using the 
following question: “Which of the following conditions are you aware of (COPD, 
depression, diabetes, hypertension, dyslipidemia and osteoporosis)?”. Prevention 
was assessed with the following question: “Which conditions to do take steps to 
prevent (heart attack/heart problems/stroke/mini-stroke, diabetes, osteoporosis)?”. 
Risk groups of COPD, depression, diabetes, hypertension, dyslipidemia and osteo-
porosis were calculated. Results were weighted/projected to represent the total 
population based on the Census Bureau. Results: In Japan, 19.8%, 79.1%, 78.4%, 
77.6%, 63.2%, 71.0% report awareness of COPD, depression, diabetes, hypertension, 
dyslipidemia, and osteoporosis, respectively. Within the risk groups only 25.1%, 
82.7%, 87.0%, 82.4%, 81.9%, 81.1% report awareness of COPD, depression, diabetes, 
hypertension, dyslipidemia, and osteoporosis, respectively. Overall, 4.4% of respond-
ents were taking steps to prevent heart problems, 7.7% were taking steps to prevent 
diabetes and 5.7% were taking steps to prevent osteoporosis. Among the COPD risk 
group, 36.5% quit smoking and 41.8% of the depression risk group spoke to a health 
care provider in the past six months. Within the diabetes risk groups 46.8% were 
taking steps to prevent diabetes. Only 6.5% of hypertension and 7.7% of dyslipidemia 
risk respondents were taking steps to prevent heart problems. In the osteoporosis 
risk group only 15.5% where taking steps to prevent osteoporosis. ConClusions: 
Data suggests a need for education programs to build awareness of chronic diseases 
in Japan. Due to the lack of knowledge of chronic diseases in Japan, prevention is 
limited especially amongst the at risk groups.
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objeCtives: The purpose of this study was to examine cost-effectiveness of 
varenicline, a pharmacotherapy developed to support smoking cessation, versus 
currently available alternatives. Methods: Two analytic decision tree models were 
used to simulate effectiveness of varenicline versus bupropion and varenicline ver-
sus nicotine replacement therapy (NRT). A 30-year Markov model with health states 
“Smoker”, “Quitter” and “Dead” was used for a hypothetical cohort of Korean smok-
ers who are over 30 years old and willing to quit smoking. The population entered in 
the model received three months of therapy. Utility values of smokers and quitters 
incorporated in the model were collected from local data. Transition probabilities 
were from clinical trials and local statistic data, and cost data were obtained from 
Korean health insurance reimbursement price list and local market price for non-
reimbursement products. The model used a 5% discount rate for costs and effective-
ness. Sensitivity analyses were conducted on various parameters such as the time 
to reach mortality rate of ex-smokers compared to that of non-smokers, time hori-
zon and discount rate. Results: The effectiveness of varenicline compared with 
bupropion and NRT was greater while it was more costly than both. The incremental 
effectiveness of varenicline versus bupropion and NRT was similar at 77,965 QALYs. 
The incremental cost of varenicline versus bupropion was 826 billion KRW and 
1,428 billion KRW with NRT. The ICER of varenicline comparing to bupropion and 
NRT were estimated at 10.6 million KRW per QALY and 19 million KRW per QALY, 
respectively. Sensitivity analyses were quite robust for all parameters but it was 
most sensitive to time horizon. ConClusions: Varenicline treatment for smoking 
cessation can be considered as cost-effective compared with existing therapies in 
Korea. The ICER becomes lower when morbidity rates of smoking related diseases 
are reflected.
